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The immunological attributes of stem cell grafts play an important role in the outcome of
allogeneic stem cell transplants. Currently, ex vivo manipulation techniques such as
bulk T-cell depletion or positive selection of CD34+ cells are utilized to improve the
immunological attributes of grafts and minimize the potential for graft-versus-host dis-
ease (GvHD). Here, we demonstrate a novel graft engineering technique, which utilizes
the immunomodulatory drug FTY720 for in vivo depletion of naı¨ve T (TN) cells from
donor G-CSF-mobilized grafts without ex vivo manipulation. We show that treatment
of donor mice with FTY720 during mobilization depletes grafts of TN cells and prevents
lethal GvHD following transplantation in a major mismatch setting. Importantly, both
stem cells and NK cells are retained in the FTY720-treated grafts. FTY720 treatment does
not negatively affect the engraftment potential of stem cells as demonstrated in our con-
genic transplants or the functionality of NK cells. In addition, potentially useful memory
T cells may be retained in the graft. These findings suggest that FTY720 may be used to
optimize the immunological attributes of G-CSF-mobilized grafts by removing potentially
deleterious TN cells which can contribute to GvHD, and by retaining useful cells which
can promote immunity in the recipient.
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Introduction
Graft engineering has played a crucial role in improving allogeneic
stem cell transplantation (ASCT) and also broadening its poten-
tial application [1]. This has been underpinned by our greater
understanding of the different cells that constitute the graft and
their contribution to alloresponses [2]. Na¨ıve T (TN) cells from
grafts are the major cells responsible for graft-versus-host disease
(GvHD), whereas other cells, such as effector memory T (TEM),
central memory T (TCM), and NK cells, have potential for pro-
moting immunity and antitumor activity, respectively [1, 3–6]. In
order to mitigate alloresponses by donor TN cells, current graft-
engineering techniques utilize ex vivo bulk T-cell depletion or
positive selection of CD34+ cells. These techniques, however, can
leave the graft devoid of useful immune cells, potentially mak-
ing the recipient more susceptible to infection and relapse [1, 2].
Techniques specifically targeting depletion of TN cells from grafts
could potentially help maximize the capacity of grafts for immune
reconstitution, antitumor activity as well as prevention of GvHD
in recipients [1, 3–6]. Bleakley et al. have recently described a
promising protocol in which TN cells are depleted from mobi-
lized grafts, but this still requires ex vivo manipulation of grafts
and complex selection strategies [7]. Simpler and effective graft
engineering techniques are therefore warranted to improve the
outcomes of ASCT.
Different T-cell subsets have distinct trafficking patterns in the
body. TN cells (CD3+ CD44−CD62L+) primarily traffic through
secondary lymphoid organs in search of their cognate antigen
[8, 9]. TCM cells (CD3+CD44+CD62L+) have a similar traffick-
ing route, while TEM cells (CD3+CD44+CD62L−) mainly surveil
the periphery and sites of inflammation [8, 9]. The trafficking
of TN cells is highly dependent on the sphingolipid metabolite
sphingosine-1-phosphate (S1P), which is present at high levels in
blood and lymph, and its receptor S1P1, which is expressed on TN
cells and other lymphocytes [10]. S1P acts as an egress factor facil-
itating the exit of TN cells from secondary lymphoid organs [10].
Disruption of the S1P/S1P1 axis leads to inhibition of this egress
and accumulation of TN cells in secondary lymphoid organs. Lym-
phocytes such as TEM cells are less affected due to their different
trafficking routes and NK cells are similarly less affected as they
utilize a different S1P receptor to exit lymph nodes [8, 11–13].
This specific property of TN cells has been exploited in relapsing-
remitting multiple sclerosis with the use of the immunomodu-
latory agent FTY720 [14]. FTY720 disrupts the S1P/S1P1 axis
by inducing internalization and degradation of the S1P1 recep-
tor [14], which leads to rapid sequestration of TN cells, as well
as B cells into secondary lymphoid organs and their depletion
from peripheral blood (PB) [11]. While the immunomodulatory
properties of FTY720 have been studied in various inflammatory
conditions as a way of impacting disease, its use in manipulat-
ing mobilized stem cell grafts has not previously been examined
[11, 12, 15, 16].
Currently, the majority of hematopoietic stem cell transplants
are performed using G-CSF-mobilized PB stem cell grafts [17].
We have previously examined the role of S1P in different forms of
mobilization and found that G-CSF mobilization is not negatively
affected by disruption of the S1P/S1P1 axis with FTY720 [18].
Due to its selective capacity to deplete TN cells from PB during
steady state, we hypothesized that FTY720 could potentially be
used during G-CSF mobilization to selective deplete these grafts
of TN cells. However, it has not been previously examined if the
capacity of FTY720 to deplete TN cells from PB is maintained dur-
ing G-CSF mobilization. In addition, there is currently no data
regarding the kinetics of this depletion. Neither the impact of
FTY720 on the engraftment capacity of mobilized stem cell grafts
nor the immunological properties of such a graft, including its
alloreactive capacity and maintenance of other lymphocyte sub-
sets such as TEM, TCM, and NK cells, have been previously exam-
ined. Here, we demonstrate the capacity of FTY720 to selectively
deplete TN cells from PB in vivo during G-CSF mobilization. We
show that NK-cell functions are not affected by FTY720 treat-
ment and that they are not depleted from the grafts following
treatment. We also show that TEM and TCM are retained in the
graft. Importantly, we demonstrate that the alloreactive capacity
of these grafts is blunted following in vivo TN cell depletion with 1-
day FTY720 treatment resulting in prevention of GvHD in a major
mismatch transplant model. Furthermore, we show that the intrin-
sic engraftment capacity of stem cells from G-CSF-mobilized grafts
is not affected by FTY720 treatment. Our data represent a proof of
concept that in vivo graft engineering of G-CSF-mobilized donor
grafts is feasible with FTY720 and that immunological attributes
of these grafts can be improved by this method.
Results
FTY720 depletes TN cells from PB but retains TEM and
NK cells at steady state and G-CSF mobilization
To assess the impact of FTY720 on different cell subsets in PB
during steady state, C57BL/6 mice were treated with FTY720
(1 mg/kg) once daily for 4 days. The next day, PB was assessed
for the different lymphocyte subsets by flow cytometry. FTY720
treatment decreased the percentage of CD3+ cells by 72% (p =
0.0056) compared to control (Fig. 1A and B). The CD3+CD62L+
TN subset was the major population depleted, decreasing by 61%
(p < 0.0001) following treatment (Fig. 1A and C). In contrast,
the relative percentages of NK and TEM (CD3+CD62L−) cells
were elevated nearly two-fold (p = 0.0066 and p < 0.0001,
respectively) by FTY720 (Fig. 1A, C, and D), likely reflecting
the depletion of TN cells. Decrease in CD62L+ cell subsets was
observed only among T cells and not NK cells (Fig. 1A, C, and D).
To determine the impact of FTY720 on lymphocyte subsets
from G-CSF-mobilized PB, mice were treated with FTY720 prior to
and concomitantly during mobilization (Fig. 2A). FTY720 signifi-
cantly reduced the percentage of T cells from mobilized PB com-
pared to untreated controls, with the greatest reduction (88.5%,
p< 0.0001) obtained after 7 days of treatment (Fig. 2B). This was
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Figure 1. Flow cytometric analysis of
T-cell and NK-cell populations in the
PB of mice treated with FTY720 or
PBS. Mice were treated with PBS or
FTY720 for 4 days prior to blood har-
vest. (A) Gating strategies for analy-
sis of flow cytometric data for T cells
and NK cells. Flow cytometric analy-
ses of (B) bulk T cells and NK cells,
(C) TN cells (CD3+CD62L+) and TEM
cells (CD3+CD62L−), and (D) CD62L+
andCD62L− NKcells are shown. Sym-
bols represent individual mice, hori-
zontal bars themeans, and error bars
±SEM. Data are representative of a
single experiment (n = 6 mice for PBS
and n = 8 mice for FTY720 group).
Datawere compared using two-tailed
unpaired Student’s t-test. §p < 0.01;
†p < 0.001.
Figure 2. Impact of FTY720 treatment on T-cell, NK-cell, and B-cell populations in G-CSF-mobilized PB. Mice were either untreated or treated
with FTY720 at 0.25, 0.5, 1, 2, and 7 days prior to PB harvest. (A) Schematic representation of different FTY720 treatment schedules relative to
G-CSF mobilization. Arrows indicate the day of initiation of daily i.p. FTY720 injections to donors prior to sacrifice (X). G denotes initiation of twice
daily s.c. injections of G-CSF to donors. Results of flow cytometric analysis of (B) bulk T cells (CD3+), (C) NK cells, (D) B cells (CD19+), (E) TN cells
(CD3+CD44−CD62L+), (F) TEM (CD3+CD44+CD62L−), and (G) TCM (CD3+CD44+CD62L+) cells from G-CSF-mobilized mice. (B–G) Bar graphs represent
cell percentages and scatter plots represent absolute counts with each symbol representing an individual mouse, horizontal bars the means, and
error bars ±SEM. Data shown are from a single experiment representative of two independent experiments performed, except for CD19+, TCM,
TEM, and TN subsets as well as the absolute cell counts which are representative of a single experiment (n = 5 mice for each treatment arm). Data
were compared using two-tailed unpaired Student’s t-test. *p < 0.05; §p < 0.01; †p < 0.001 for each group compared with the untreated control.
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also reflected in a reduction in T-cell numbers, which decreased
by up to 96% (p < 0.0001) following 7 days of treatment (Fig.
2B). B-cell percentages and numbers were also reduced by up
to 78.2% (p < 0.0001) and 92.5%, (p < 0.0001) respectively,
after 7-day treatment compared to untreated controls (Fig. 2D).
In contrast, the percentage of NK cells was significantly elevated
by 3.8-fold (p < 0.0001) compared with untreated mobilized con-
trols (Fig. 2C). However, numbers of NK cells in mobilized PB
were not significantly altered (Fig. 2D). To better assess the effect
of FTY720 treatment on TN, TEM as well as TCM subsets in G-CSF-
mobilized PB, we used CD44 and CD62L staining (Fig. 2E–G). TN
(CD3+CD44−CD62L+) were decreased as early as 6 h post-FTY720
treatment and the greatest reduction observed following 7 days of
treatment (Fig. 2E) with percentage and numbers decreasing by
up to 95% (p < 0.0001) and 99.8% (p < 0.0001), respectively.
TEM cells (CD3+CD44+CD62L−) became the predominant T-cell
population in the mobilized blood post-treatment, increasing in
percentage up to 2.6-fold (p < 0.0001) after 1 day of treatment
and up to three-fold (p < 0.0001) following 7 days of treatment.
The numbers of TEM cells, however, were reduced by 74.8% (p <
0.001) and 88.3% (p < 0.001) following 1 and 7 days of treat-
ment, respectively (Fig. 2F). TCM cells (CD3+CD44+CD62L+) ini-
tially increased in percentage 1.3-fold (p < 0.001) in the mobi-
lized blood 6 h post-FTY720 treatment but were reduced by up
to 36.4% (p < 0.001) following 7 days of treatment. In contrast,
their numbers decreased by up to 90.5% (p < 0.0001) after 1
day of treatment and up to 97.3% (p < 0.0001) after 7 days of
treatment (Fig. 2G). These results demonstrate that NK cells are
maintained in the G-CSF-mobilized blood following FTY720 treat-
ment and that some TEM and TCM cells may be retained in the graft
after FTY720 treatment due to their different clearance kinetics
compared with TN cells.
Differences in the clearance rates of TEM and TCM cells com-
pared with TN cells suggest that memory T cells may be retained
in FTY720-treated grafts. To investigate this, we assessed levels of
OVA-specific CD8+ T cells in G-CSF-mobilized grafts from OVA-
immunized mice untreated or treated with FTY720 1 day prior
to sacrifice. The percentage of pentamer+CD8+ T cells tended to
decrease in PB of controls following mobilization (Fig. 3), while
the percentage of pentamer+CD8+ T cells tended to increase in
mice following mobilization and 1 day of FTY720 treatment (Fig.
3, not significant). The trend of increased amounts of antigen-
specific T cells in mice treated with FTY720may reflect the seques-
tration of certain cell populations such as TN cells from the mobi-
lized PB to organ tissue.
Together, these data suggest that FTY720 treatment can effec-
tively deplete TN cells from G-CSF-mobilized grafts and that
antigen-specific memory T cells can be retained.
FTY720 treatment does not affect NK-cell functionality
at steady state and after G-CSF mobilization
To examine the functionality of NK cells retained following
FTY720 treatment, we used an in vivo NK killing assay with
Figure 3. Effect of FTY720 treatment on antigen-specific CD8+ TEM cells
in G-CSF-mobilized grafts. Gating strategy (top) and percentage (bot-
tom) of OVA-pentamer+CD8+ T cells in PB pre- and post-G-CSF mobi-
lization from untreated or 1-day FTY720-treated donors preimmunized
with OVA. Data are representative of a single experiment (n = 5 donors
per group). Data were compared using two-tailed unpaired Student’s
t-test.
MHC-deficient splenocytes as targets [19]. In contrast to NK-
depleted control mice, both PBS and 5-day FTY720-treated mice
manifested significant killing of transplanted MHC-deficient
splenocytes (Fig. 4A).
The impact of FTY720 on the alloreactivity of NK cells was also
examined in a transplant setting. BALB/c Rag2−/−/gcR−/− (BRG)
recipient mice were transplanted with T-cell-depleted (TCD)
splenocytes from FTY720-treated, G-CSF-mobilized C57BL/6
donor mice and inoculated with a luciferase+ BALB/c-derived B
cell lymphoma cell line A20, 1 day post-transplant. Biolumines-
cence imaging 14 days post-A20 inoculation showed that TCD
splenocytes from FTY720/G-CSF-treated mice decreased tumor
burden compared with A20-only control or transplanted mice
treated with an NK-depleting Ab (Fig. 4B and C).
The functionality of purified human NK cells following 19-h
FTY720 treatment in vitro was assessed against K562 targets.
Neither FTY720 nor FTY720P (the active phosphorylated form),
at any of the physiologically relevant doses tested, had negative
effects on NK-cell degranulation or cytokine production (Fig. 4D).
Together, these data demonstrate that FTY720 has no detrimental
effects on NK-cell function under steady state or during G-CSF
mobilization and suggests that they may contribute to allore-
sponses in the recipient under the appropriate transplant setting.
Selective depletion of TN cells from G-CSF-mobilized
PB grafts prevents GvHD
To investigate the capacity of FTY720 to minimize the GvHD
potential of G-CSF-mobilized grafts in a major mismatch setting,
lethally irradiated BALB/c recipients were injected intravenously
with mobilized PB from C57BL/6 donors treated with PBS or
C© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2016. 00: 1–12 Clinical immunology 5
Figure 4. Assessment of in vivo NK-cell functionality following FTY720 treatment. (A) Killing capacity of NK cells from PB of C57BL/6 mice treated
with FTY720 or PBS. Treated recipients were injected with an equal mixture of syngeneic target splenocytes (MHC−CFSEhigh versus MHC+CFSElow).
The relative rejection of MHC− splenocytes 1 day post-injection was assessed by comparing the ratio of CFSEhigh and CFSElow cells (defined as
killing ratio) from recipient blood with preinoculate by flow cytometry. C57BL/6 mice treated with an NK-cell-depleting Ab were used as control.
Symbols in scatter plots represent individual mice, horizontal bars the means, and error bars ±SEM (n = 8 mice for PBS and FTY720 groups; n
= 4 mice for NK-cell-depleted controls; combined data from two experiments). Data were compared using two-tailed unpaired Student’s t-test.
†p< 0.001. (B) Bioluminescence imaging of BRGmice, transplanted with grafts from FTY720-treated G-CSF-mobilized donors, 14 days post-injection
with the luciferase+ BALB/c-derived B cell lymphoma cell line A20. (C) Graphical representation of bioluminescence intensity from (B). Symbols
in scatter plots represent individual mice, horizontal bars the means, and error bars ±SEM from a single experiment. Data were compared using
one-tailed unpaired Student’s t-test. *p < 0.05; §p < 0.01. (D) Degranulation (CD107a) and cytokine production (IFN-γ and TNF-α) by purified human
NK cells cultured in media or different concentrations (10 or 100 nM) of FTY720 or FTY720P for 19 h against K562 targets was assessed by flow
cytometry. NK cells without targets were used as controls. Data are shown as mean ± SEM of n = 5 donors pooled from two experiments. Data
were compared using two-tailed unpaired Student’s t-test.
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Figure 5. Effect of FTY720 graft engineering on the outcome of allogeneic stem cell transplantation. Recipient BALB/c mice received G-CSF-
mobilized PB from PBS- or FTY720-treated C57BL/6 donors. Recipients injected with TCD BM served as controls. (A–C) Donors were treated with
FTY720 for 2 days prior to and concomitantly during 5 days of G-CSF mobilization. Recipients did not receive an NK-depleting Ab. (D–I) Donors
were treated with FTY720 only on the last day of the 5-day G-CSF mobilization prior to sacrifice. (D–F) Recipients received one dose of anti-asialo
GM1 3 days prior to transplant (n = 6 per group). (G–I) Recipients received anti-asialo GM1 5 and 1 day prior to transplant (n = 6 per group except
TCD BM (n = 4)). (A, D, and G) Survival curves, (B, E, and H) clinical scores on sacrifice, and (C, F, and I) weight curves for the various recipient BALB/c
mice are shown. (J) Percent of donor cells (CD45.2+ H-2Kb+) >100 days post-transplant in PB of BALB/c recipients treated with anti-asialo GM1 5
and 1 day prior to transplant. Symbols in scatter plots represent individual mice, horizontal bars the means, and error bars ±SEM of the indicated
numbers of mice, from a single experiment. Survival times were compared using log-rank survival statistics. Reconstitution was compared using
two-tailed unpaired Student’s t-test. §p < 0.01; †p < 0.001; n.s.: not significant.
FTY720. Blood from two donor mice was used per recipient. Ini-
tially, blood from 7-day FTY720-treated mobilized donors was
used. FTY720 treatment prevented lethal GvHD even at a high
irradiation dose of 9.5 Gy (Fig. 5A–C). However, no long-term
donor reconstitution followed in either FTY720 grafts or TCD BM
controls except from one animal (data not shown) suggesting that
both grafts were rejected. Graft rejection, which can be medi-
ated by recipient NK cells, is a complication of T-cell depletion
[20]. In order to protect grafts from rejection, recipient mice were
lethally irradiated and injected with an NK-depleting Ab (anti-
asialo GM1), according to manufacturer’s recommendations, 3
days before transplant. Irradiation was reduced to 8 Gy to min-
imize potential conditioning-related problems with the delayed
transplant. FTY720 administration was reduced to a single dose,
1 day prior to graft harvest. A single dose of FTY720 was effec-
tive in preventing lethal GvHD, since all recipients of FTY720-
treated grafts survived up to 100 days without signs of GvHD
(Fig. 5D–F). In contrast, all PBS controls succumbed to GvHD by
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Figure 6. Histological assessment of skin, gastrointestinal tract, and liver of recipient mice transplanted with FTY720- or PBS-treated, G-CSF-
mobilized donor grafts. Recipientmicewere transplantedwith PBS-, FTY720-treatedmobilized grafts or TCDBMgrafts. Recipientmice transplanted
with mobilized grafts from PBS-treated donors and which succumbed to GvHD between day 8 and day 38 were sacrificed and tissue samples
obtained for histology. Mice transplanted with mobilized grafts from FTY720-treated donors or TCD BM transplanted controls did not succumb
to GvHD and were sacrificed after >100 days post-transplant. Representative histological sections of (A) skin, (C) large intestine, and (E) liver
from recipients are shown. Pathology scores of (B) skin, (D) large intestine, and (F) liver sections from recipient mice transplanted with PBS-,
FTY720-treated G-CSF-mobilized grafts, or TCD BM grafts. Donors were treated with FTY720 only on the last day of the 5-day G-CSF mobilization
prior to sacrifice. Recipients either received one dose of anti-asialo GM1 3 days prior to transplant (n = 6 per group) or anti-asialo GM1 at 5 and 1
days prior to transplant. Symbols in scatter plots represent individual mice, horizontal bars the means, and error bars ±SEM of n = 6 per group
except TCD BM, n = 4, combined data from two experiments. Histopathological scores were compared using one-way ANOVA with Bonferroni
correction. †p < 0.001. Scale bars, 200 μm.
day 37 (Fig. 5D–F). However, grafts from neither FTY720-treated
donors nor TCD BM controls, were reconstituted. Therefore, we
repeated the same experiment but with anti-asialo GM1 injec-
tions 5 days and 1 day prior to transplantation. Again, GvHD
was averted in recipients of FTY720-treated grafts (Fig. 5G–I). In
this experiment, recipients of FTY720-treated grafts and recipi-
ents of TCD BM both showed partial donor reconstitution after
sacrifice >100 days post-transplant (Fig. 5J). The low reconstitu-
tion of both grafts suggested a general problem with graft rejec-
tion rather than a drug-specific effect on engraftment. Accord-
ingly, at least 10 × 106 TCD BM cells are required for successful
donor engraftment in such a major mismatch setting with lower
doses compromising donor reconstitution [21]. Figure 6 demon-
strates the capacity of FTY720 to prevent GvHD in skin (A and B),
gastrointestinal tract (C and D), and liver (E and F). Together,
these data demonstrate that FTY720 treatment in donors during
G-CSF mobilization can prevent GvHD in recipients up to 100 days
post-transplantation.
FTY720 treatment does not affect donor cell
reconstitution
To assess the impact of FTY720 treatment on grafts in a
more permissive setting, we performed transplants in congenic
(CD45.1) recipients, using mobilized donor PB from two C57BL/6
mice, either treated with PBS or FTY720 for 1 day, per recip-
ient. The level of donor reconstitution was assessed 18 weeks
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Figure 7. Assessment of long-term donor stem cell reconstitution from FTY720- or PBS-treated G-CSF-mobilized grafts. (A) Congenic transplant of
mobilized grafts, from 1-day PBS- or FTY720-treated C57BL/6 donors into CD45.1 recipients. Donor reconstitution in PB 18 weeks post-transplant
was evaluated by flow cytometry. (B) Secondary transplants of BM cells from primary mice 18 weeks post-transplant. Percent donor reconstitution
in PB 18 weeks postsecondary transplant is shown. (C) Representative dot plots of donor-derived cells (CD45.2+) in the PB of a secondary recipient
(CD45.1+) 18 weeks post-transplant with 5 × 106 BM cells from a primary recipient mouse. (D) Donor-derived (CD45.2+) CD3+, CD19+, and GR-1+
cells in PB of secondary recipients 18 weeks post-transplant with BM from primary recipients transplanted with either FTY720- or PBS-treated
mobilized grafts. Symbols in scatter plots represent individual mice, horizontal bars the means, and error bars ±SEM of samples from a single
experiment. Data were compared using two-tailed unpaired Student’s t-test. n.s.: not significant.
post-transplant. Secondary transplants using BM from primary
recipients were performed to assess long-term donor reconstitu-
tion capacity. FTY720-treated grafts and PBS controls displayed
similar levels of donor cell reconstitution in recipients 18 weeks
following primary and secondary transplantation (Fig. 7A and B).
The reconstitution of T and B cells as well as granulocytes was
also comparable between the two grafts (Fig. 7C and D).
Discussion
Here we demonstrate a novel graft engineering strategy, which
exploits the normal trafficking properties of different immune cell
populations and stem cells to derive a graft product with improved
immune characteristics and reduced potential for inducing GvHD.
By using FTY720 to disrupt the S1P/S1P1 axis during G-CSF mobi-
lization, wewere able to effectively deplete donor-mobilized grafts
of TN cells in vivo without the need for further ex vivo manipu-
lation. The depletion was sufficient to prevent GvHD in a major
mismatch model. To our knowledge, this is the first demonstra-
tion of the immunomodulatory capacity of FTY720 during G-CSF
mobilization and how it can be utilized to optimize the immuno-
logical attributes of mobilized grafts to prevent GvHD. Others have
previously examined the use of FTY720 to try and mitigate GvHD
[15, 22]. In these models, however, FTY720 was used in recipi-
ents following ASCT [15, 22]. This required prolonged treatment
of recipients with FTY720, which was also found to alter immune
reconstitution [22]. This is avoided in our system as potentially
alloreactive cells are depleted from the graft prior to transplant
avoiding the need for prolonged FTY720 treatment of the recipi-
ent. Additionally, we demonstrate that FTY720 treatment does not
negatively impact the engraftment capacity of stem cells. We also
show that NK cells, which have potential for promoting immunity,
antitumor and anti-GvHD effect aremaintained inmobilized grafts
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following FTY720 treatment and that FTY720 does not impair
their function. TEM and TCM cells, which were decreased in mobi-
lized PB following treatment, although at a slower rate than TN
cells, may also be retained and therefore potentially contribute
to promoting immunity in the recipient. It has previously been
shown by Sawicka et al. that TREG are preferentially enriched in
PB following FTY720 treatment during steady state [23]. Although
the presence of TREG was not examined in this study, it is possi-
ble that they are also retained in the graft and may contribute to
dampening of GvHD.
Different graft engineering strategies have been examined and
developed in order to prevent GvHD in ASCT [1]. These strate-
gies, however, rely on ex vivo manipulation of grafts. Tradition-
ally, total T-cell depletion has been performed but more recently
selective depletion of TN cells has also been investigated following
successful data from animal models [3, 7]. In support of this, our
selective in vivo depletion of TN cells with FTY720 also resulted in
effective prevention of GvHD, without requiring ex vivo manipu-
lation of grafts. This has important implications for the simplifica-
tion and potentially, cost-effectiveness of future graft engineering
protocols.
It has been suggested that >2-log depletion of bulk T cells
is minimally required to avoid GvHD [24, 25]. Although we did
not achieve such a high reduction in bulk T cells from the G-
CSF-mobilized grafts, we did achieve at least a 2-log reduction
in TN cells, which was sufficient to prevent GvHD in our major
mismatch transplant model. This suggests that the level of TN cell
depletion, rather than that of bulk T cells, is important for preven-
tion of GvHD. Currently, the level of TN cell depletion required
to prevent GvHD is unknown but our results provide a start-
ing point for investigations into further defining this threshold.
It has also previously been shown that bulk T-cell depletion of
grafts alone can lead to problems with post-transplant EBV-related
lymphoproliferative disorders due to an imbalance between T-
and B-cell numbers in infused products [1]. FTY720 adminis-
tration can potentially address this problem as we have shown
that it can also deplete B cells significantly from G-CSF-mobilized
PB.
Harnessing the potential of NK cells in ASCT for the treat-
ment ofmalignant diseases is currently under intense investigation
[26, 27]. The capacity of FTY720 to maintain NK cells in G-CSF-
mobilized grafts suggests they would be available to contribute to
promoting immunity, antitumor responses and GvHD-modulating
activity in the correct transplant setting.
Donor lymphocyte infusions using antigen-specific TEM are now
being explored to combat immunosuppression-related complica-
tions following ASCT [1, 6]. Our data show that treatment with
FTY720 for 1 day is sufficient to prevent GvHD but also retain some
antigen-specific memory T cells. Thus, using this protocol it may
be possible to retain antigen-specific memory T cells from donors
with preexisting immunity to help promote recipient immunity
without the need for ex vivo isolation, again potentially decreas-
ing the complexity of these procedures. This also suggests that
FTY720 may be useful when given to donors in order to deplete
the PB of TN and B cells while retaining NK and memory T cells
for improving the immunological attributes of donor lymphocyte
infusions aimed at combating infections.
We have previously demonstrated that mobilization of
hematopoietic progenitor cells with G-CSF is not affected by
FTY720 [18]. Similarly, we did not observe differences in the
engraftment rate of G-CSF-mobilized grafts from FTY720-treated
mice compared with PBS-treated controls in our congenic trans-
plant model. This supports our previous findings that mobilization
with G-CSF is not impaired by FTY720 and also demonstrates that
FTY720 treatment does not impair the engraftment of these grafts.
While the engraftment of FTY720-treated grafts was unaffected in
our congenic transplant model, we observed much lower engraft-
ment rates in our major mismatch model. It has been demon-
strated that recipient NK-cell-mediated graft rejection is increased
following T-cell depletion of grafts [20, 28]. Accordingly, donor
engraftment of both FTY720-treated grafts and TCD BM controls
was improved following NK depletion of recipient mice. Future
studies will be required to assess how recipient NK-mediated graft
rejection could be further avoided in such a graft.
Although this novel approach shows promise, several hurdles
must be overcome for its clinical potential to be realized. Cur-
rently, good safety data are only available regarding the effect of
each individual agent in healthy volunteers, but not in combina-
tion. Thus, safety of the G-CSF and FTY720 combination must be
determined. In our study, no obvious detrimental effects accom-
panied administration of the combined agents to animals. Another
major hurdle is prevention of graft rejection. Better conditioning
strategies specifically targeting recipient NK cells will be neces-
sary to ensure successful engraftment of such a graft and retention
of the potentially useful donor NK cells. Combining this strategy
with mesenchymal stem cell infusions may be a potential solu-
tion, which could also synergize with this protocol to promote
greater anti-GvHD effects, provide graft protection, and improve
engraftment and donor reconstitution [29].
In summary, our study is a proof of concept that demonstrates
for the first time how differences in the trafficking properties of
stem and immune cells can be utilized for donor in vivo graft
engineering of G-CSF-mobilized stem cell grafts. It shows that
FTY720 administered during G-CSF mobilization can improve the
immunological attributes of these grafts and prevent GvHD in the
absence of ex vivo manipulation. These results may be applicable
to the development of future transplantation and immunotherapy
protocols and strongly suggest that clinical investigation into the
use of FTY720 for improvement of ASCT is warranted.
Materials and methods
Reagents
FTY720 (fingolimod) was purchased from Cayman Chemical (Ann
Arbor, MI) and G-CSF (filgrastim) from Amgen (Solna, Sweden).
Luciferin was from Gold Biotechnology (St. Louis, MO). H-2Kb -
SIINFEKL - Pentamer - R-PE was from ProImmune (Oxford, UK)
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and OVA peptides were from GenScript (Piscataway, NJ). The
Dynabeads Mouse Pan T (Thy1.2) kit and CountBright Absolute
Counting Beads were from Invitrogen (Lidingo¨, Sweden), and the
human NK-cell isolation kit was from Miltenyi Biotec (Lund, Swe-
den). The murine NK-depleting Ab anti-NK1.1 (clone PK136) was
a kind gift from Dr Benedict Chambers and anti-asialo GM1 was
from Wako (Neuss, Germany). PolyI:C was a kind gift from Dr
Annette Sko¨ld. The anti-murine Ab anti-H-2Kb FITC, anti-CD45.2
APC, CD45.1 biotin, anti-CD3 PerCP Cy5.5, CD3 APC-Cy7, anti-
CD62L PE-Cy7, and anti-NK1.1 Pacific Blue were from Biolegend
(San Diego, CA). Anti-CD19 PE, anti-Gr-1 PE-Cy7, anti-CD8 PE-
Cy5, and anti-B220-APC were from e-Bioscience (San Diego, CA).
Anti-CD19 APC and anti-CD44 BV510 and anti-human; anti-CD56
(clone NCAM 16.2), anti-CD107a (clone H4A3) and anti-IFN-
γ (clone 25723.11) were from BD Biosciences (San Jose, CA).
Anti-CD3 (clone UCHT1) was from Dako (Glostrup, Denmark),
and anti-TNF-α (clone MP6-XT22) was from eBioscience. CFSE
and Streptavidin-qDot 605 were obtained from Life Technologies
(Carlsbad, CA).
Animals
All mice (C57BL/6, B6.SJL-Ptprca Pep3b/BoyJ [CD45.1],
B6.Kb-/− Db-/−, BALB/c, BALB/c Rag2−/−γc−/− [BRG]) were bred
and maintained at the Department of Microbiology, Tumor and
Cell Biology, Karolinska Institutet. Mice were used at 8–12 weeks
of age and sex-matched. All animal experiments were approved
by the Animal Ethics Committee of Stockholm in Sweden and con-
ducted in accordance with institutional guidelines for animal care
and use.
Mobilization, drug treatment, and absolute cell counts
Mice were mobilized by subcutaneous injection of G-CSF
(125 μg/kg) twice daily for 5 days unless otherwise specified and
sacrificed the following day. FTY720 (1 mg/kg) was administered
intraperitoneally daily either alone or concurrently during mobi-
lization as specified. Absolute cell counts were performed using
CountBright Absolute Counting Beads according to the manufac-
turer’s instruction.
OVA immunization and memory T-cell assays
Mice were vaccinated subcutaneously in both right and left flank
with 2 × 106 BM-derived dendritic cells pulsed with 1 μM OVA
peptide (SIINFEKL) twice with 1 day in between. Six weeks later,
PB was assessed for SIINFEKL-specific CD8 T cells by pentamer
staining. Twenty days later, mice were mobilized with G-CSF and
left untreated or treated with FTY720 as described above. Mice
were sacrificed 1 day post-FTY720 treatment and PB collected
by cardiac puncture and analyzed for the SIINFEKL specific CD8
T cells. Pentamer staining of PB CD8 T cells was performed accord-
ing to the manufacturer’s instruction and in combination with CD8
and B220 monoclonal Ab.
NK assays
An in vivo CFSE-based NK killing assay was performed as pub-
lished [19]. Briefly, recipient C57BL/6 mice were treated with
FTY720 or PBS for 5 days. The following day, splenocytes from
MHC-deficient C57BL/6 (susceptible targets) and wild-type mice
(resistant targets) were obtained and labeled 1:1 (15 × 106
each) with 5 μM (CFSEhigh) and 0.5 μM (CFSElow) of CFSE dye
(Molecular probes), respectively. Following washes, they were
injected into the recipient mice. The ratio between the two pop-
ulations before co-injection was determined by flow cytometry.
NK-depleted (anti-NK1.1) recipient mice were used as negative
controls. One day post-injection, mice were sacrificed and bled.
The ratio of CFSEhigh and CFSElow cells present in PB was assessed
by flow cytometry and compared with the pre-inoculation ratio.
The killing ratio was calculated by dividing the ratio between tar-
gets 1 day postinjection by that of the preinoculate.
The in vivo killing capacity of NK cells from G-CSF-mobilized
C57BL/6 mice treated for 1 day with FTY720 was assessed by
transplanting 10 × 106 TCD splenocytes intravenously into BRG
recipient mice. Splenocytes were depleted of T cells according to
manufacturer’s instructions (Dynabeads Mouse Pan T (Thy1.2)
kit; Invitrogen). Recipients were also treated with 500 μg of
polyI:C for NK-cell activation. Recipients receiving the same cells
but also injected intravenously with 500 μg of anti-NK1.1 were
used as controls. The following day, recipient mice were inocu-
lated intravenously with 1 × 103 luciferase+ A20 cells (BALB/c
derived B cell lymphoma cell line provided by Prof. A. Grandien).
A20 cells were maintained in complete medium (RPMI 1640 with
10% heat inactivated FCS and 2 mM L-glutamine; all from Invit-
rogen) supplemented with 0.05 mM 2-ME (Sigma-Aldrich). Mice
injected with luciferase+ A20 cells alone also served as controls.
Tumor burden was assessed by injecting mice with 150 mg/kg
luciferin and assessing bioluminescence with the IVIS Spectrum
CT (Caliper Life Sciences/Perkin Elmer, Hopkinton, MA).
Human NK cells were isolated from PB by negative selec-
tion according to manufacturer’s instructions (NK-cell isolation
kit; Miltenyi Biotec). Approval was obtained from the Regional
Ethics Review Board for the use of PB mononuclear cells from
healthy donors. NK cells were cultured in complete medium alone
or with FTY720 or FTY720P at the specified concentrations for
19 h. Degranulation and cytokine responses of NK cells against
K562 (obtained from ATCC and maintained in complete medium)
targets were then assessed [30].
ASCT and GvHD
Mobilized grafts were transplanted into BALB/c recipients 3 days
after lethal irradiation (8 Gy). Recipients were also treated either
once (-3 days) or twice (-5 and -1 days) before transplant with
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anti-asialo GM-1 (according to manufacturer’s specification) to
deplete NK cells. Blood from two donor C57BL/6 mice (approxi-
mately 1.6 mL) was used per BALB/c recipient. On average 18.4 ×
106 cells (range 10–23.8 × 106) from FTY720-treated mobilized
blood and 22.5 × 106 cells (11–33.6 × 106) from PBS-treated
mobilized blood was transplanted per recipient. Donor blood
cells, after RBC lysis with CaCl2, were washed in PBS and
resuspended in 100 μL PBS prior to intravenous injection into the
recipient. TCD BM cells were used as controls and 1 × 106 cells
were injected per recipient. Mice were assessed for disease every
2 days initially and daily following disease progression. Mice were
examined for changes in weight, movement, posture, activity, skin
integrity, piloerection, eye inflammation, appetite, respiration,
bowel and urinary function. Mice not succumbing to disease after
40 days were monitored weekly until sacrificed after 100 days.
Assessment of GvHD pathology
Liver, large intestine, and skin from the abdominal region were
fixed in 10% formalin for 24 h and embedded in paraffin. Five-
micrometer sections were made from each organ, stained with
H&E and slide mounted with DPX (Sigma-Aldrich). Sections were
examined under 16×magnification using a LEICADM400Bmicro-
scope and scored blind. Skin sections were scored on the basis of
the following criteria: epidermis (0, normal; 1, foci of interface
damage in less than 20% of section with occasional necrotic ker-
atinocytes; 2, widespread interface damage in more than 20%
of section); dermis (0, normal; 1, slightly altered with mildly
increased collagen density; 2, markedly increased collagen den-
sity); subcutaneous fat (0, normal; 1, reduced number of normal
adipocytes; 2, serous fat atrophy); follicles (three to four fields)
(0, normal number of hair follicles, approximately ten per field;
1, between five and ten follicles per field; 2, <5 follicles per field)
and inflammation (0, none; 1, focal infiltrates; 2, widespread infil-
trates). Livers were assessed for bile duct injury (manifested by
nuclear hyperchromasia, lymphocytic infiltrate) and inflammation
(infiltrating lymphocytes, neutrophils, and eosinophils). Disease
scores of between 0 and 4 were assigned based on the number of
tracts involved and severity of disease in each tract (0, none; 1,
few tracts with mild disease; 2, numerous tracts involved but mild
disease; 3, injury in most tracts; 4, severe involvement of most
tracts). Intestinal GvHD was scored on the basis of inflammation
(0, none; 1, mild; 2, moderate; 3, severe without ulceration; 4,
severe with ulceration).
Congenic transplants
Lethally irradiated (11 Gy) congenic (CD45.1+) recipients were
transplanted on the same day with PB from two donor C57BL/6
(CD45.2+) mice. PB was obtained from G-CSF-mobilized mice
treated with PBS or FTY720 1 day prior to PB harvest. Donor
blood was RBC lysed and resuspended in PBS prior to intravenous
injection into recipient as described previously. The percentage
of CD45.2+ cells in recipient PB was assessed via flow cytometry,
18 weeks post-transplant to determine donor reconstitution. Sec-
ondary transplants were performed in lethally irradiated CD45.1+
recipients using 5 × 106 BM cells from primary recipient mice and
donor reconstitution was assessed 18 weeks post-transplantation.
The percentage of CD45.2+ cells in recipient PB along with CD3+,
CD19+, and GR-1+ cells was assessed 18 weeks post-transplant to
determine donor reconstitution.
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